UNSPSC 51292020: Citalopram hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DY48G26JY. European Medicines Agency schedules Citalopram hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16412MIG. Citalopram hydrochloride generally arises in the molecular formula C20H21FN2O.CLH. The term 'citalopram hydrochloride' is a European Pharmacopoeia designation.

Most nations, for tariff and trade purposes, schedule citalopram hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, CITALOPRAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCC1(C2CCC(CC2CO1)C#N)C3CCC(CC3)F.CL.

UNSPSC 51292020 Citalopram hydrochloride, a Commodity code, represents a narrow pharmaceutical ingredient category that state and local governments procure primarily as part of broader pharmaceutical supply contracts rather than as a standalone product line. Recent state and local opportunities tagged under this code show a significant mismatch: the actual solicitations involve naloxone kits, drug deactivation systems, multi-source generic pharmaceuticals, and over-the-counter products—none of which are citalopram hydrochloride. The code appears to see limited direct procurement activity at the state and local level, with issuing bodies approaching pharmaceutical supply through cooperative purchasing vehicles, group purchasing organizations, and authorized wholesale distribution channels rather than direct manufacturer contracts for specific active pharmaceutical ingredients.

The recent opportunities illustrate the operational landscape: Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline. The MMCAP procurement, spanning participating state and local facilities including Oregon, demonstrates the cooperative purchasing model that dominates state and local pharmaceutical procurement, requiring products through authorized wholesalers and emphasizing price competitiveness, cGMP certification, and Drug Supply Chain Security Act compliance. Geographic activity centers on Florida, Texas, and Minnesota, though the code shows little genuine recent solicitation activity specific to citalopram hydrochloride itself.